Cephalon Boosts Cancer Pipeline With Acquisition Valued At Up to $525 Million
The specialty biopharma has gained two promising oncology drugs through the acquisition of privately-held Gemin X
The specialty biopharma has gained two promising oncology drugs through the acquisition of privately-held Gemin X